{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Non-Hodgkin%27s+Lymphoma&page=2", "query": { "condition": "Relapsed Non-Hodgkin's Lymphoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Non-Hodgkin%27s+Lymphoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T16:08:12.310Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05702853", "title": "Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Non Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Cyclophosphamide injection", "type": "DRUG" }, { "name": "Fludarabine Injection", "type": "DRUG" }, { "name": "CD19-CD34t metabolically programmed CAR transduced T-cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2023-11-06", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-07-23T16:08:12.310Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05702853" }, { "nct_id": "NCT01840566", "title": "High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Carmustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "19-28z T CELLS", "type": "BIOLOGICAL" }, { "name": "Autologous Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2013-04", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-07-23T16:08:12.310Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01840566" }, { "nct_id": "NCT00006083", "title": "Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous/Nonmalignant Condition", "Unspecified Adult Solid Tumor, Protocol Specific", "Veno-occlusive Disease" ], "interventions": [ { "name": "Fragmin", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-04", "completion_date": "2000-11", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-07-23T16:08:12.310Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006083" }, { "nct_id": "NCT00179673", "title": "Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkins Lymphoma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2005-06", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2025-05-13", "last_synced_at": "2026-07-23T16:08:12.310Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Berkeley, California • Fountain Valley, California + 8 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00179673" }, { "nct_id": "NCT00547196", "title": "AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Leukemia", "Lymphoma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "Fractionated total body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "0 Years to 120 Years" }, "enrollment_count": 10, "start_date": "2005-08-16", "completion_date": "2024-05-28", "has_results": true, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-07-23T16:08:12.310Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Duarte, California", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00547196" }, { "nct_id": "NCT01614197", "title": "A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia, Acute, Childhood", "Lymphoblastic Lymphoma", "Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 16, "start_date": "2015-07-03", "completion_date": "2020-09-04", "has_results": true, "last_update_posted_date": "2023-07-27", "last_synced_at": "2026-07-23T16:08:12.310Z", "location_count": 25, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01614197" }, { "nct_id": "NCT00002779", "title": "Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "octreotide acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "1998-02", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-07-23T16:08:12.310Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002779" }, { "nct_id": "NCT00787761", "title": "Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Disorders", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic HSCT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 24, "start_date": "2007-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2012-10-01", "last_synced_at": "2026-07-23T16:08:12.310Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787761" }, { "nct_id": "NCT02706405", "title": "JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma" ], "interventions": [ { "name": "Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2016-11-15", "completion_date": "2021-05-28", "has_results": true, "last_update_posted_date": "2022-08-24", "last_synced_at": "2026-07-23T16:08:12.310Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706405" }, { "nct_id": "NCT02702141", "title": "A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma", "DLBCL", "Diffuse Large B-cell Lymphoma", "Grade 3 Follicular Lymphoma" ], "interventions": [ { "name": "SGN-CD19B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2016-02", "completion_date": "2018-07-10", "has_results": false, "last_update_posted_date": "2018-08-13", "last_synced_at": "2026-07-23T16:08:12.310Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Duarte, California • Jacksonville, Florida + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02702141" } ] }